Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy

Authors


  • Potential conflict of interest: Dr. Shawcross advises Norgine.

    The patients described in this case series were enrolled in a study approved by the North East London Research Ethics committee (Ref Number 08/H0702/74). It was performed in accordance with the declaration of Helsinki and fully informed written consent was obtained from each patient.

No abstract is available for this article.

Ancillary